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Background: The clinical and economic burden associated with invasive and non-invasive pneumococcal and
non-typeable Haemophilus influenzae (NTHi) diseases is substantial in the Latin America and Caribbean region,
where pneumococcal vaccines have only been introduced to a few countries. This study analyzed the cost-effectiveness
and cost utility of three different pneumococcal conjugate vaccines (PCVs) for Peru.
Methods: A Markov model that simulated the disease processes in a birth cohort over a lifetime, within
1,128 month cycles was used to evaluate the cost-effectiveness of 10-valent pneumococcal NTHi protein D conjugate
vaccine (PHiD-CV) and 7- and 13-valent PCVs (PCV-7 and PCV-13). Expected quality-adjusted life years (QALYs),
cost-savings and incremental cost-effectiveness ratios (ICERs) were calculated.
Results: Without vaccination, pneumonia was associated with the greatest health economic burden (90% of
QALYs lost and 63% of lifetime direct medical costs); while acute otitis media (AOM) was responsible for 1% of
QALYs lost and 25% of direct medical costs. All vaccines were predicted to be cost-effective for Peru, with PHiD-CV
being most cost-effective. PHiD-CV was predicted to generate 50 more QALYs gained and required a reduced
investment (−US$ 3.4 million) versus PCV-13 (discounted data), and was therefore dominant and cost saving.
The probabilistic sensitivity analysis showed that PHiD-CV generated more QALYs gained at a reduced cost than
PCV-13 in 84% of the simulations and less QALYs gains at a reduced cost in 16%. Additional scenarios using
different assumptions on vaccine efficacies based on previous evidence were explored, but no significant
change in the overall cost-effective results were observed.
Conclusions: The results of this modeling study predict that PCVs are likely to be a cost-effective strategy to
help relieve the epidemiological and economic burden associated with pediatric pneumococcal and NTHi diseases for
Peru. PHiD-CV is likely to be a dominant (better health gains at a reduced net cost) intervention compared to PCV-13
or PCV-7. The most significant drivers for these results are the better health and economic profile of PHiD-CV against
AOM and its reduced cost per dose available through the PAHO Revolving Fund in the LAC region.
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Streptococcus pneumoniae is one of the leading causes
of morbidity and mortality in Latin American children.
O’Brien et al. reported that, in the year 2000, S. pneumo-
niae infections led to 648,000 cases and 24,300 deaths
due to pneumonia, 9,500 cases and 4,500 deaths due
to meningitis, and 11,700 severe cases and 4,300 deaths
of non-pneumonia, non-meningitis invasive pneumo-
coccal disease (IPD) among children aged <5 years in the
Americas World Health Organization (WHO) Region [1].
Furthermore, Valenzuela et al. estimated the annual
burden of pneumococcal diseases to include 330,000
pneumonia cases, 1,200 cases of sepsis, 3,900 cases of
meningitis, and 1.3 million cases of acute otitis media
(AOM) among children aged <5 years in the Latin America
and Caribbean (LAC) region [2]. The annual number of
deaths due to pneumococcal disease was 12,000-28,000 [2].
Although a 7-valent pneumococcal conjugate vaccine
(PCV-7) (Prevenar®, Pfizer, USA) has been licensed in the
LAC region for several years, it has only recently been
introduced into a few national immunization programs.
Peru was one of the few LAC countries that introduced
PCV-7, in 2009 [3], and is traditionally using the Pan
American Health Organization (PAHO) revolving fund
for its vaccination program [4]. However, it has been re-
ported that the introduction of PCV-7 into national pro-
grams does not sufficiently reduce pneumococcal disease
burden, because of the low vaccine coverage reached in
these programs and the low number of pneumococcal
serotypes covered by the vaccine [5,6].
New PCVs are now available against these diseases with
broader serotype coverage. Firstly, PHiD-CV (Synflorix™,
GlaxoSmithKline Biologicals, Belgium), a 10-valent pneumo-
coccal non-typeable Haemophilus influenzae protein D
conjugate vaccine that includes three additional serotypes
(1, 5, and 7 F) compared to PCV-7 (serotype 4, 6B, 9 V,
14, 18C, 19 F and 23 F) and uses protein D from non-
typeable Haemophilus influenzae (NTHi) as a carrier pro-
tein, which may offer additional protection against NTHi
[7]. Secondly, PCV-13 (Prevenar 13®, Pfizer/Wyeth, USA),
a PCV composed of six additional capsular S. pneumoniae
polysaccharide serotypes (1, 3, 5, 6A, 7 F and 19A) com-
pared to PCV-7, which are individually conjugated to
non-toxic diphtheria as a carrier protein [8].
Reducing and eliminating vaccine-preventable diseases
requires evidence-based and informed policy decision
making. The National Institute of Health of Peru has re-
cently completed a limited economic evaluation of the
new pneumococcal vaccines, and concluded that PHiD-CV
and PCV-13 would be more cost-effective than PCV-7
in terms of preventing pneumonia hospitalizations [9].
The aim of the current study is to provide comprehen-
sive data on the comparative cost utility and cost-
effectiveness analysis of the different PCVs in order tofacilitate the decision-making process of immunization
policy at a national level.
Methods
Modeling approach
An age-compartmental, deterministic and static cohort
Markov model developed in MS Excel® (Microsoft
Corporation, Redmond, WA) was used to assess the
health and economic impact of PCVs in Peru. The model
simulated the disease process of invasive diseases (ID),
community acquired pneumonia (CAP), and AOM caused
by S. pneumoniae and NTHi in a birth cohort over a
lifetime with 1,128 month cycles (or 94 years) to calcu-
late expected costs and quality-adjusted life years (QALYs)
over time.
The impact of vaccination was assessed in a cohort
(vaccinated or unvaccinated) that was followed over a
lifetime, as previously described [10,11]. A direct vaccine
effect was estimated as a reduction in the incidence
of ID, CAP, and AOM. Six diseases (pneumococcal menin-
gitis, NTHi meningitis, pneumococcal bacteremia, NTHi
bacteremia, CAP, and AOM) were followed through
specific disease outcomes and treatment pathways. The
model compared different accumulated conditions over
the lifetime of a birth cohort - unvaccinated and vacci-
nated with PCV-7, PCV-13, or PHiD-CV. Table 1 pre-
sents details of the base-case analysis [5,12,13].
Model inputs
Epidemiological burden
The epidemiological data for ID and pneumonia (Additional
file 1: Table S1, Additional file 1: Table S2 and Additional
file 1: Table S3) used to populate the Markov model
were taken from a previous study in six Latin American
countries (Mexico, Brazil, Argentina, Chile, Colombia,
and Peru) [14], which reviewed databases from the
Ministry of Health and published and unpublished studies
from Peru using the Delphi method [15].
Country-specific data on AOM were not available.
Therefore, the average incidence rate from three Latin
American AOM studies (carried out in Brazil, Mexico
and Chile) [16-18] was used (Additional file 1: Table S4).
This average showed a peak incidence rate of AOM
during the first year of life (8,943.5 cases per 100,000
infants). In our simulation, 60% of the studied cohort
will suffer from AOM that will impact to the health
system. The incidence of tympanocentesis and seque-
lae were calculated by multiplying AOM incidence by
the corresponding percentages provided by Delphi
panels. The frequency of NTHi and S. pneumoniae in
AOM was obtained from an international review (32.3%
for NTHi and 35.9% for S. pneumoniae [19]) because
country-specific epidemiological data for AOM were
not available.
Table 1 Assumptions and main parameters used in the
base-case analysis
Parameter Assumptions and values used in the base case
Country Peru
Population Newborn cohort of 2007 (500,700) [12]
Perspective Payers of the healthcare system
Time horizon Lifetime
Comparators No vaccination, PCV-7, PCV-13, and PHiD-CV
Indirect effects None considered in the base-case analysis
NTHi ID efficacy 35.3% for PHiD-CV [13]
Outcomes ID: meningitis and bacteremia (including long-term
sequelae for meningitis)Ambulatory and hospitalized
PneumoniaAOM (including long-term sequelae and
myringotomy)
Cross protection Considered for 6A and 19A in ID
Vaccine coverage 95% of the cohort receives full schedule for PHiD-CV
and PCV-13; PCV-7 was studied with 83% coverage [5]
Vaccination schedule 2 + 1, same for the 3 vaccines: two doses at 2 and
4 months of age and a booster dose at 12 months
of age
Vaccine price Vaccine prices per dose for PCV-13 (US$ 16.34) and
PHiD-CV (US$ 14.24) were obtained from the PAHO
Revolving Fund 2012, and PCV-7 (US$ 20.00) from the
PAHO Revolving Fund 2010 (last year of availability)
Duration of immunity 9 years, with vaccine efficacy modeled as previously
shown for all the outcomes evaluated [11]
Discounting 3.5% for costs and health events
AOM, acute otitis media; ID, invasive disease; NTHi, non-typeable Haemophilus
influenzae; PAHO, Pan American Health Organization; PCV-7, 7-valent pneumo-
coccal conjugate vaccine; PCV-13, 13-valent pneumococcal conjugate vaccine;
PHiD-CV, 10-valent pneumococcal non-typeable Haemophilus influenzae protein
D conjugate vaccine; WHO, World Health Organization.
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from data from the Latin American surveillance system
(SIREVA) promoted by PAHO [20]: the ratio of S. pneu-
moniae to NTHi meningitis was 11:1 and S. pneumoniae
to NTHi bacteremia was 17:1 (please see Additional file
1 for calculation).
S. pneumoniae serotype distribution was obtained from
the Latin American Network for Surveillance of Pneumo-
nia & Bacterial Meningitis Agents (SIREVA II). We used
average data specifically reported for Peru for 2000–2006
(n = 222) (Additional file 1: Table S5) [21,22]. The epi-
demiological data used to calibrate the model for Peru
was collected prior to the introduction of PCV-7 in 2009,
as were all the other epidemiological data used. Peru
reports to this network typing results of 17–50 cases
per year. Although minor differences are reported in
type distribution year by year, no clear trend was observed
over time (even for serotypes 6A & 19A) and the annual
sample size is not adequate to assure that the scenario
of any individual year will represent a significant epi-
demiological change. Therefore, we decided to use averagedata of pneumococcal types distribution covering many
years before vaccine introduction in the analysis.
Economic burden
Average costs of treatment for the different outcomes
were estimated for Peru using micro-costing methods
with unit costs from the three health sectors of Peru
(public, private, and EsSalud), considering their reported
coverage. Rates of service utilizations were obtained from
Delphi panels [15,23], as previously described [14]. Costs
(Additional file 1: Table S6) were obtained in 2009
Nuevos Soles and translated to 2009 US$ using the ex-
change rate for December 2009 (US$ 1 = 2.78 Nuevos Soles).
Vaccine efficacy assumptions
Vaccine efficacy varies with age as previously described
[11]. Monthly cycles were chosen in order to estimate
the effect of the vaccination precisely in the first 2 years
of life. The vaccine is given at ages 2, 4, and 12 months.
In order to account for partial early protection at ages 2
and 4 months, we subdivided the model into monthly
cycles. It is important to estimate the effect of the vac-
cines in the <1-year age group precisely because the
burden of disease amongst pediatric population is the
highest in this age group. Vaccine efficacy input data for
each of the vaccines assessed in this study were obtained
or estimated from previously published papers [13,24-32]
and abstracts [33-35] of clinical trials and a review [31].
The base-case analysis considers vaccine efficacy against
S. pneumoniae related IPD and AOM, and against all-
cause hospitalized pneumonia. We also assumed, in the
base-case analysis, that the use of protein D from NTHi
as a carrier protein in PHiD-CV may offer additional
protection against NTHi disease (AOM & ID) [7,13].
Key model assumptions were validated with international
pneumococcal vaccine and modeling experts during 2007–
2008 (see Additional file 1 for details on experts consulted),
and have been previously published [10,11].
Vaccine efficacy against ID
Vaccine efficacy against IPD was based on the serotype-
specific efficacies reported for PCV-7 in a matched
case–control study [24] and the serotype distribution
of S. pneumoniae from SIREVA II [21,22] (Additional
file 1: Table S5). Vaccine efficacy for the additional sero-
types in the new vaccines was assumed to be the average
of the vaccine efficacies observed for the serotypes in-
cluded in PCV-7 (94.7%) [24]. The vaccine efficacy of
PHiD-CV against NTHi-associated ID was assumed to
be the same as that reported for NTHi-associated AOM
(35.3%) [13]. This assumption was considered to be
conservative as the vaccine efficacy of PCVs against ID
is much higher than for mucosal diseases. For ex-
ample, vaccine efficacy of PCV-7 against IPD (vaccine
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diseases has been reported to be 58% (in pneumococcal
AOM) [13,32].
Finally, similar cross-protection against S. pneumoniae
serotypes 6A and 19A for ID was considered for PCV-7
and PHiD-CV. Immunogenicity studies have shown that
PHiD-CV provides cross-reacting functional (opsonopha-
gocytic) antibodies against 6A and 19A [36,37]. These
studies have shown that PHiD-CV and PCV-7 provide
similar levels of cross-functional antibodies against sero-
type 6A, but PHiD-CV provides higher levels of cross-
reacting functional antibodies against serotype 19A than
PCV-7. Cross-protection of PCVs against S. pneumoniae
type 6A has been reported in several studies [24,32,38],
and Hausdorff et al. have suggested that cross-protection
against S. pneumoniae serotype 19A is likely [39]. In
accordance with guidelines on the evaluation of new
vaccines developed by the European Medicines Agency
(EMEA) [40], in the absence of specific efficacy studies,
immunogenicity data were considered and cross-protection
levels of 76% against S. pneumoniae type 6A and 26%
against S. pneumoniae type 19A for PCV-7 and PHiD-CV
in ID were assumed, based on Whitney et al. [24].
Vaccine efficacy against CAP
Vaccine efficacy against CAP was based on the results
of the recently completed COMPAS study, a Latin
American trial of PHiD-CV [33-35]. Based on this study,
vaccine efficacy against hospitalized all-cause pneumonia
was assumed to be 23.4%, and against all-cause ambula-
tory pneumonia, 7.3% (similar for the three vaccines).
These efficacies were used for PCV-7, PCV-13 and
PHiD-CV, based on two PCV-7 studies [25,26], three
studies of an experimental 9-valent PCV [27-29], a study
with an experimental 11-valent conjugated vaccine [30],
the COMPAS study of PHiD-CV [33-35], and a Cochrane
Collaboration review [31], which show no clear relation-
ship between vaccine efficacy against pneumonia and the
serotypes contained in the PCV.
Vaccine efficacy against AOM
Vaccine efficacies of PCV-13, PCV-7, and PHiD-CV
against AOM were extrapolated from a PCV-7 trial [32]
and one of an 11-valent precursor to PHiD-CV [13].
Vaccine efficacy against AOM-related pneumococcal
serotypes included in all three vaccines was assumed to
be 58%, as previously shown [13,32]. Vaccine efficacy
against AOM associated with the pneumococcal types
not included in these vaccines was −33% (serotype re-
placement effect), as shown in the PCV-7 study [32].
Although PHiD-CV did not show any serotype replace-
ment effect [13], it was included in the model for
PHiD-CV following expert opinion. Vaccine efficacies
against NTHi AOM were assumed to be 35.3% forPHiD-CV (based on the 11-valent precursor to PHiD-CV
study [13]) and −11% for PCV-7 and PCV-13 (based on
the PCV-7 study [32], incorporating a replacement ef-
fect as was found in this study). The vaccine coverage
on the pneumococcal types isolated in AOM was calcu-
lated using the pneumococcal type prevalence in AOM
described in a meta-analysis of AOM etiology in Latin
America by Bardach et al. [41]. Overall, the final estimated
coverages for PCV-7, PHiD-CV, and PCV-13 were 69.8%,
76.2%, and 89.5%, respectively.
Vaccine-related costs
Vaccine prices per dose were obtained from the 2012
PAHO Revolving Fund (RF) for PCV-13 (US$ 16.34) and
PHiD-CV (US$ 14.24) (the first year with these two vac-
cines available at the PAHO RF), and from the PAHO
Revolving Fund 2010 (the last year with this vaccine
available at the PAHO RF) for PCV-7 (US$ 20.00). We
decided to use the PAHO RF framework for the analysis
because Peru and many other Latin American countries
buy vaccines under this environment. Vaccine costs also
included a 10% vaccine wastage cost and US$ 1 adminis-
trative costs per dose for either vaccine [42]. The base-
case of the analysis was performed from a healthcare
payer (Ministry of Health) perspective using direct
medical costs.
Cost-effectiveness analysis
Cost-effectiveness of the three vaccines (PCV-7, PCV-13,
and PHiD-CV) was assessed against no vaccination, using
a three-dose (2 + 1) vaccination schedule for each vaccine
at 2, 4, and 12 months of age (Table 1). Vaccination cover-
age (three doses) of 83% was used for PCV-7, as reported
by WHO Vaccine-Preventable Diseases Monitoring Sys-
tem for 2010 [5], and 95% was estimated for PHiD-CV
and PCV-13 vaccines (Table 1).
The utility decrements (Additional file 1: Table S7)
used for each outcome analyzed were obtained from
international sources [43-46] due to lack of local data. A
3.5% discount rate for cost and health outcomes was
applied to estimate the incremental cost-effectiveness
ratios (ICERs). The gross domestic product (GDP) per
capita (2009 US$) for the cost-effectiveness threshold
was obtained from the International Monetary Fund
(US$ 4,356 per capita for Peru) [47]. Cost-effectiveness
thresholds of 1 or 3 GDP per capita were used, following
the recommendations of the Commission on Macroeco-
nomics and Health of the WHO [48,49].
Sensitivity analyses
Univariate sensitivity analysis was completed for all of
the model input parameters. Each parameter was varied
up and down from the base-case value, and for each
change, the ICER was re-estimated and compared to the
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bust when ICER variations did not modify interpretation
of the cost-effectiveness of vaccination. The list of model
parameters and their associated sampling uncertainty
included in the 1-way sensitivity analysis are shown in
Additional file 1: Table S8.
Probabilistic sensitivity analysis (PSA) was performed
by recording the results of 1,000 Monte Carlo simula-
tions, each of which simultaneously sampled each of the
model’s input parameters from an appropriate probabil-
istic distribution (normal distribution for vaccine effi-
cacy, triangular distribution for disease incidence and
costs, beta distribution for disutility). PSA was con-
ducted to evaluate the effect of the uncertainty of input
data while comparing the vaccines. PSA was completed
for the base-case health outcomes and cost results com-
paring PHiD-CV with no vaccination and comparing
PHiD-CV with PCV-13 for Peru.
Scenario analysis
In addition to the base-case scenario, 10 scenarios of
interest were also analyzed:
1. A discount rate of 5% for costs and health effects
(this higher discount rate is being recommended in
some Latin American countries).
2. No vaccine efficacy of PHiD-CV against NTHi ID,
and against NTHi in ID & AOM.
3. Costs from a social perspective (productivity losses
were included, considering average annual salary for
parents, employment rate, and average time lost
from work for working parents of sick children).
4. Herd effect (evaluated as a fixed incidence reduction
of IPD of 15.4% and 29.0% among children <5 years
and ≥5 years, respectively, based on the experience
reported by CDC in the USA [50,51]). The net
indirect effect on IPD was not included in base-case
analysis for vaccine comparison since the potential
difference in herd protection induced by these
vaccines is not known. The inclusion or exclusion
of equal (not differential) herd effect for all vac-
cines will not impact on the results because the
incremental differences between them would be
the same with or without inclusion of the
indirect effect.
5. No cross protection to pneumococcal type 6A in ID.
6. No cross protection to pneumococcal type 19A in ID.
7. A 3 + 1 vaccination scheme (at 2, 4, and 6 months of
age with a booster dose at 12 months). The
modeling of vaccine efficacies for this schedule has
been explained previously [11].
8. Similar vaccine efficacies of PHiD-CV and PCV-13
against IPD.
9. No efficacy of PCV-13 against serotype 3 IPD.10. Equal vaccine cost per dose for all vaccines (US$ 14.24),
to determine costs differences generated by
vaccines at equal price per dose.
Results
ID, CAP, and AOM burden in Peru without vaccination
Table 2 presents the modeled health burden of pneumo-
coccal and NTHi disease during the first 10 years of life
in Peru. Although IPD is considered to generate signifi-
cant mortality, in reality, pneumonia is responsible for
the majority (93%) of pneumococcal/NTHi deaths in Peru
(Table 2). The lifetime burden associated with pneumonia
was the highest, accounting for 90% of all QALYs lost
(data not shown). IPD (meningitis and bacteremia)
accounted for 9% of all QALYs lost, and AOM, a mild
but frequent condition, only accounted for 1% of all
QALYs lost. Regarding the lifetime costs to the health
system, pneumonia was responsible for 63% of all direct
medical costs, AOM for 25%, and ID for 12% (data
not shown).
Effects of vaccines on ID, CAP, and AOM
Vaccination with PCV-7, PCV-13, or PHiD-CV is estimated
to reduce ID cases (pneumococcal and NTHi meningitis
and bacteremia), by 25%, 35%, and 34%, respectively
(Table 2). Vaccination with any of the three vaccines is
expected to reduce hospitalized and ambulatory pneu-
monia cases by around 12-14% and 2-3%, respectively
(Table 2). The burden associated with AOM is expected
to decrease by 3.1%, 6.6%, and 11.9% for PCV-7, PCV-13,
and PHiD-CV, respectively, with reductions in myringo-
tomies of 12.2%, 26.0%, and 46.6%, respectively (Table 2).
Since vaccine efficacies against S. pneumoniae for AOM
were similar for all three vaccines, these differences are
mostly explained by the difference in efficacy against
NTHi shown by PHiD-CV.
Effects of vaccine on deaths and QALYs gained
The results of this modeling exercise suggest that vaccin-
ation is expected to avert approximately 28.1% (PCV-7),
38.6% (PCV-13), and 37.8% (PHiD-CV) of deaths attrib-
uted to ID (pneumococcal and NTHi meningitis and
bacteremia) (Table 2). This would fall slightly to 37.0%
for PHiD-CV if efficacy against NTHi is not considered.
PCV-13 and PHiD-CV are expected to avert 12.6% of
deaths associated with pneumonia, while PCV-7 is esti-
mated to avert 11.0% (Table 2). Overall, PCV-13 is ex-
pected to prevent 0.8 more deaths than PHiD-CV (the
model estimated that 0.7 additional deaths would occur
with PHiD-CV if efficacy to NTHi ID is not considered),
with both vaccinations saving nearly 190 lives during
the first 10 years of life of the cohort.
The greatest QALYs (morbidity and mortality) gained
by vaccination in Peru is expected to be associated with
Table 2 Predicted health impact of PCVs in Peru during the first 10 years of life (undiscounted data)
No vaccination PCV-7 PCV-13 PHiD-CV
Casesa Rateb Casesa Rateb Averted (%) Casesa Rateb Averted (%) Casesa Rateb Averted (%)
Cases
Pneumococcal meningitis 177 35.4 142 28.4 19.8 129 25.8 27.1 131 26.2 26.0
NTHi meningitis 16 3.2 16 3.2 0.0 16 3.2 0.0 14 2.8 12.5
Pneumococcal bacteremia 495 98.9 350 69.9 29.3 295 58.9 40.4 303 60.5 38.8
NTHi bacteremia 30 6.0 30 6.0 0.0 30 6.0 0.0 25 5.0 16.7
Hospitalized pneumonia 37,110 7,412 32,585 6,508 12.2 31,930 6,377 14.0 31,930 6,377 14.0
Ambulatory pneumonia 39,352 7,859 38,404 7,670 2.4 38,268 7,643 2.8 38,267 7,643 2.8
AOM 306,989 61,312 297,535 59,424 3.1 286,598 57,239 6.6 270,573 54,039 11.9
Myringotomies 7,193 1,437 6,315 1,261 12.2 5,325 1,064 26.0 3,838 767 46.6
Deaths
Pneumococcal meningitis 9.7 1.9 7.2 1.4 26.2 6.2 1.2 36.0 6.4 1.3 34.5
NTHi meningitis 1.6 0.3 1.6 0.3 0.0 1.6 0.3 0.0 1.4 0.3 10.9
Pneumococcal bacteremia 76.2 15.2 53.4 10.7 30.0 44.7 8.9 41.3 46.1 9.2 39.6
NTHi bacteremia 3.0 0.6 3.0 0.6 0.0 3.0 0.6 0.0 2.5 0.5 17.2
Pneumonias 1,212.0 242.1 1,078.4 215.4 11.0 1,059.0 211.5 12.6 1,059.0 211.5 12.6
Total 1,302.5 260.1 1,143.5 228.4 12.2 1,114.6 222.6 14.4 1,115.4 222.8 14.4
aCases and deaths during the first 10 years of life.
bRates expressed per 100,000 individuals.
AOM, acute otitis media; NTHi, non-typeable Haemophilus influenzae; PCV-7, 7-valent pneumococcal conjugate vaccine; PCV-13, 13-valent pneumococcal conjugate
vaccine; PHiD-CV, 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine.




Pneumococcal ID QALYs - morbidity 259.3 356.1 340.2
QALYs - mortality 1,613.0 2,223.0 2,129.0
NTHi ID QALYs - morbidity 0 0 12.3
QALYs - mortality 0 0 44.0
Pneumonia QALYs - morbidity 41.5 47.4 47.4
QALYs - mortality 8,526.0 9,759.0 9,759.0
AOM QALYs - morbidity 50.5 109.0 196.0
Total QALYs gained 10,490.3 12,494.5 12,527.9
Total LYs gained 11,847.0 14,000.0 13,942.0
aUndiscounted data.
AOM, acute otitis media; ID, invasive disease; LY, life year; NTHi, non-typeable
Haemophilus influenzae; PCV, pneumococcal conjugate vaccine; PCV-7, 7-valent
pneumococcal conjugate vaccine; PCV-13, 13-valent pneumococcal conjugate
vaccine; PHiD-CV, 10-valent pneumococcal non-typeable Haemophilus influenzae
protein D conjugate vaccine; QALY, quality-adjusted life year.
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prevention of ID and AOM account for 18-21% and
0.5-1.6% of QALYs gained, respectively (Table 3). Over
the life-time of the cohort, PCV-13 is expected to avert
53.6 more QALYs (morbidity and mortality) associated
with ID than PHiD-CV, but the latter is expected to avert
87.0 more QALYs (morbidity) associated with AOM than
PCV-13 (undiscounted data). Overall, total QALYs gained
are 2,004.2 and 2,037.6 for PCV-13 and PHiD-CV,
respectively, compared with PCV-7 (Table 3).
PCV-13 is predicted to generate 14,000 LYs gained,
PHiD-CV is predicted to generate 13,942 LYs gained, and
PCV-7 is predicted to generate 11,847 LYs gained, with
most of them linked to pneumonia for the three vaccines
(Table 3).
Treatment costs averted, vaccine costs, and net costs
Using undiscounted data, PCV-7 vaccination is expected
to save US$ 1.4 million in direct medical costs over the
life-time of the cohort, PCV-13, US$ 1.9 million, and
PHiD-CV, US$ 2.3 million (Table 4). This is largely attrib-
utable to cost savings for pneumonia (US$ 1.0-1.2 million;
51-73% of total) and AOM (US$ 0.2-0.9 million; 17-41%
of total) (Table 4). Not surprisingly, PHiD-CV is pre-
dicted to avert more AOM costs than PCV-7 or PCV-13
(US$ 935,558 vs US$ 240,962 and US$ 521,999, respect-
ively) due to its effect on NTHi AOM (Table 4). Although
the studied vaccines present different coverage against thepneumococcal types prevalent in ID in Peru, they do not
show large differences in the predicted economic burden
averted (US$ 0.1-0.2 million) (Table 4).
Considering the PAHO Revolving Fund Program cost
for each vaccine during 2012, the cost of the vaccination
program would be US$ 3.1 million lower for PHiD-CV
than for PCV-13 (US$ 22.4 million vs US$ 25.5 million)
(Table 4).
Table 4 Economic results of PCVs for Peru
PCV-7 PCV-13 PHiD-CV
Costs averteda % Costs averteda % Costs averteda %
All ID 138,603 10.0 190,893 10.2 188,650 8.3
Meningitis (all) 19,386 1.4 26,641 1.4 26,392 1.2
Meningitis sequelae (all) 80,789 5.8 110,947 5.9 109,835 4.8
Bacteremia (all) 38,428 2.8 53,305 2.9 52,423 2.3
Pneumonia 1,008,424 72.7 1,153,782 61.8 1,153,845 50.7
All AOM 240,962 17.4 521,999 28.0 935,558 41.1
Total direct medical costs 1,387,989 100 1,866,674 100 2,278,053 100
Vaccination cost −23,727,362 −25,487,635 −22,393,203
Net total cost −22,339,373 −23,620,961 −20,115,150
aUndiscounted costs in 2009 US$.
A negative value indicated costs incurred.
AOM, acute otitis media; ID, invasive disease; PCV-7, 7-valent pneumococcal conjugate vaccine; PCV-13, 13-valent pneumococcal conjugate vaccine; PHiD-CV, 10-valent
pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine.
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http://www.biomedcentral.com/1471-2458/13/1025The predicted net total cost of a PCV vaccination pro-
gram (considering direct medical cost savings and vac-
cination costs) is predicted to be lowest for PHiD-CV in
Peru (US$ 20.1 million vs US$ 22.3 million for PCV-7
and US$ 23.6 million for PCV-13; Table 4).Cost utility and cost-effectiveness analysis
Tables 5 and 6 present the cost utility and cost-effectiveness
analysis expressed as ICERs in US$ per QALY (Table 5) or
LY (Table 6) saved versus no vaccination and comparing
the three vaccines. PCV-13 was estimated to generate 719
more QALYs gained than PCV-7 at an additional invest-
ment of US$ 1.3 million, making it a cost-effective interven-
tion compared to PCV-7 for Peru (Table 5). PHiD-CV
was estimated to generate 769 more QALYs gained than
PCV-7 with a reduced investment (−US$ 2.1 million); in
addition, PHiD-CV was estimated to generate 50 more
QALYs gained than PCV-13 with a reduced investment
(−US$ 3.4 million) (Table 5). The negative ICER for
PHiD-CV in Table 5 shows that PHiD-CV is predicted
to be cost saving per QALY gained compared to PCV-7
and PCV-13 for Peru when quality of life is considered.Table 5 Cost-effectiveness of PCVs (per QALY gained), in incr
QALYs Costa Differences vs no v
QALYs Costa
No vaccine 11,586,536 23,570,416 - -
PCV-7 11,590,206 45,641,050 3,670 22,070,634
PCV-13 11,590,925 46,952,004 4,389 23,381,588
PHiD-CV 11,590,975 43,544,180 4,439 19,973,764
aCosts in 2009 US$ (discounted data).
ICER, incremental cost-effectiveness ratio; PCV, pneumococcal conjugate vaccine; PCV-
conjugate vaccine; PHiD-CV, 10-valent pneumococcal non-typeable Haemophilus influTable 6 shows that PHiD-CV is also predicted to be
the most cost-effective vaccine when quality of life is not
considered (US$ 4,293 per LY). Furthermore, PHiD-CV
is predicted to be cost saving compared to PCV-7,
generating 699 additional LYs at a reduced investment
(−US$ 2.1 million) (Table 6). Although PCV-13 is pre-
dicted to save 20 more LYs than PHiD-CV, at an incremen-
tal investment of US$ 3.4 million (compared to PHiD-CV),
the ICER of PCV-13 versus PHiD-CV is US$ 170,391 per
LY saved (greater than the 3 GDP per capita threshold
for Peru) (Table 6).
Overall, all three vaccines are predicted to be cost-
effective for Peru compared with no vaccination, using the
GDP/Capita threshold developed by the WHO [48,49].
However, PHiD-CV is predicted to be the most cost-
effective vaccine, whether costs per QALY or costs per LY
are considered.Sensitivity analysis
Figure 1 displays the results of the one-way sensitivity
analysis to determine the effects of uncertainty in model
input parameters on the cost-effectiveness results of theeasing order of QALYs
accine Incremental differences vs PCV-7 scenario
ICER QALYs Costa ICER
- - - -
6,014 - - -
5,327 719 1,310,954 Dominated
4,500 50 −3,407,824 −2,727
7, 7-valent pneumococcal conjugate vaccine; PCV-13, 13-valent pneumococcal
enzae protein D conjugate vaccine; QALY, quality-adjusted life year.
Table 6 Cost-effectiveness of PCVs (per LY gained) in increasing order of LYs
LYs Costa Difference vs no vaccine Incremental differences vs PCV-7 scenario
LYs Costa ICER LYs Costa ICER
No vaccine 12,988,553 23,570,416 - - - - - -
PCV-7 12,992,507 45,641,050 3,954 22,070,634 5,582 - - -
PHiD-CV 12,993,206 43,544,180 4,653 19,973,764 4,293 699 −2,096,870 −3,000
PCV-13 12,993,226 46,952,004 4,673 23,381,588 5,004 20 3,407,824 170,391
aCosts in 2009 US$ (discounted data).
ICER, incremental cost-effectiveness ratio; LY, life year; PCV, pneumococcal conjugate vaccine; PCV-7, 7-valent pneumococcal conjugate vaccine; PCV-13, 13-valent
pneumococcal conjugate vaccine; PHiD-CV, 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine.
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http://www.biomedcentral.com/1471-2458/13/1025model. The analysis of the ICERs of PHiD-CV versus no
vaccination (Figure 1A) shows that only the vaccine effi-
cacy against hospitalized pneumonias may significantly
modify its value. Nevertheless, the ICER in the worst
scenario (with lower efficacy to hospitalized pneumonias),
is not greater than the 3 GDP per capita threshold of
cost-effectiveness. Similar results are observed for PCV-13
(Figure 1B).
The PSA on the ICER of PHiD-CV versus no vaccin-
ation (Figure 2A) in the base-case scenario confirms that
PHiD-CV is a cost-effective intervention in 99.9% of
simulations. In addition, Figure 2B, which compares the
ICERs of PHiD-CV versus PCV-13, shows that PHiD-CV0
A
% reduction in CAP hospitalizations (2+1), all vaccines (95% CI)
Hospitalizations for CAP (-/+ 20%)
Vaccine administration & wastage costs, all vaccines (-/+ 100%)
Case fatality ratio - CAP (-/+ 20%)
Ramp up efficacy assumptions, all vaccines (-/+ 20%)
Death ratio - general population (+/-20%)
Incidence - bacteremia (-/+ 50%)
GP visits for AOM (-/+ 50%)
Case fatality ratio - bacteremia (-/+ 20%)
Efficacy all vaccines vs AOM due to NTHi (2+1 regimen) (95% CI)
0
B
Incidence - meningitis (-/+ 50%)
% reduction in CAP hospitalizations (2+1), all vaccines (95% CI)
Hospitalizations for CAP (-/+ 20%)
Vaccine administration & wastage costs, all vaccines (-/+ 100%)
Case fatality ratio - CAP (-/+ 20%)
Ramp up efficacy assumptions, all vaccines (-/+ 20%)
Death ratio - general population (+/-20%)
Incidence - bacteremia (-/+ 50%)
GP visits for AOM (-/+ 50%)
Case fatality ratio - bacteremia (-/+ 20%)
Figure 1 One-way sensitivity analysis of ICERs. A: PHiD-CV vs no vaccin
13 vaccine and in B shows the ICER PHiD-CV vaccine. AOM, acute otitis medi
eral practitioner; ICER, incremental cost-effectiveness ratio; PCV-13, 13-vale
cal non-typeable Haemophilus influenzae protein D conjugate vaccine.generates more QALYs gained at a reduced investment
in 84% of the simulations and less QALYs gained at a
reduced investment in 16% of the simulations.
Scenario analysis
Figure 3 shows the results of the different scenarios of
interest analyzed. Using a discount rate of 5% reduced
(by 26%) the estimated number of QALYs gained with
PHiD-CV. The largest difference was found when con-
sidering the indirect costs using a social perspective.
This made PHiD-CV a cost-saving intervention compared
to no vaccination (Figure 3A). When herd effects were




































Cost (US$) per QALY gained
Low values
High values
e; B: PCV-13 vs no vaccine. Dashed line in A shows the ICER for PCV-
a; CAP, community acquired pneumonia; CI, confidence interval; GP, gen-
nt pneumococcal conjugate vaccine; PHiD-CV, 10-valent pneumococ-
Figure 2 Probabilistic sensitivity analysis. A: ICER of PHiD-CV vs no vaccine; B: ICER of PHiD-CV vs PCV-13. The diagonal grey line indicates the
cost-effectiveness threshold. ICER, incremental cost-effectiveness ratio; PCV-13, 13-valent pneumococcal conjugate vaccine; PHiD-CV, 10-valent
pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine; QALY, quality-adjusted life year.
Gomez et al. BMC Public Health 2013, 13:1025 Page 9 of 14
http://www.biomedcentral.com/1471-2458/13/1025seen (21%). A 3 + 1 schedule increased the number of
QALYs gained (32%) and also the investment required
(35%) (Figure 3A). In the scenario with equal pricing of
PHiD-CV and PCV-13, the investment needed for PCV-13
is reduced by 13%, but it is still higher than the invest-
ment required for PHiD-CV, due to AOM cost offsets.
The scenario with no efficacy against NTHi in ID and
AOM shows a decrease in the QALYs gained by PHiD-CV
with minor changes in costs. Finally, the scenarios with
no efficacy for PHiD-CV against NTHi ID, no efficacy
for PCV-13 against type 3 IPD, no cross protection to
6A and 19A, or with similar efficacies to IPD between
vaccines do not present significant changes compared
to the base-case analysis.
Discussion
The adoption of a new vaccination program requires
evidence-based and informed policy decision-making.
The aim of our project was to provide cost-utility and
cost-effectiveness data on the new PCVs to help the
decision-making process at the national level of Peru.
Although this is purely a modeling exercise, some con-
clusions can be highlighted. Pneumonia was the main
driver for pneumococcal disease burden in Peru. With-
out vaccination, it was estimated to generate 90% of all
QALY lost and 63% of all direct medical costs in Peru.
PHiD-CV and PCV-13 are predicted to prevent a similar
number of deaths, but PHiD-CV is predicted to generate
33.4 additional QALYs at a reduced cost of US$ 3.5 million
(undiscounted data). The benefits observed for PHiD-CV
over PCV-13 are mainly due to the vaccine effects on
AOM. PHiD-CV is predicted to generate 87.0 additional
QALYs (~80% more than PCV-13) and save US$ 0.4 million(~80% more than PCV-13) associated with the prevention
of AOM. Other results were similar for PHiD-CV and
PCV-13. However, a PHiD-CV vaccination program would
cost US$ 3.1 million less than a PCV-13 vaccination
program, based on the 2012 vaccine prices of the PAHO
Revolving Fund, resulting in an estimated net total cost
saving for PHiD-CV versus PCV-13 of US$ 3.5 million
(undiscounted data).
In addition, all vaccines are predicted to be cost-
effective for Peru, and close to the highly cost-effective
threshold, generating major health and economic bene-
fits for this Latin American country. A similar result was
obtained in a recent study carried out for PHiD-CV in
several Latin American countries including Peru [14].
When only LYs lost were considered (i.e., no quality of
life factors analyzed), both vaccines were predicted to be
cost-effective for Peru, PHiD-CV more so than PCV-13,
based on the additional economic burden averted and the
reduced cost per dose. The net total cost required for
PHiD-CV vaccination is predicted to be US$ 3.4 million
less than for PCV-13. Additionally, PCV-13 is predicted
to generate 20 additional LY compared to PHiD-CV at
an extra cost of US$ 3.4 million, giving an ICER of
US$ 170,391 per LY saved (over the cost-effectiveness
threshold defined for Peru), and PHiD-CV is predicted
to be cost saving compared to PCV-7 (generates 699
additional LYs at a reduced cost of US$ 2.1 million).
Considering quality of life in the analysis, PHiD-CV and
PCV-13 present similar health benefits related to ID and
pneumonia outcomes. However, PHiD-CV shows a slightly
better health profile based on its effects on AOM. In
addition, PHiD-CV has a much better economic profile,














PHiD-CV Fixed Herd Effects in ID























































PHiD-CV No VE to NTHi in ID
PHiD-CV No VE to NTHi in ID & AOM
PCV13 No VE to St. Pneumoniae type 3
PCV13 Equal Vaccine Pricing : 14,24
PHiD-CV Similar efficacy to ID than PCV13
PHiD-CV No Cross Protection for 6A










































Figure 3 Scenario analysis comparing PHiD-CV and PCV-13 vs no vaccine. A. contains scenarios generating greater variations on health effects and
costs. B. contains scenarios generation smaller variations on health effects and costs. ID, invasive disease; NTHi, non-typeable Haemophilus influenzae;
PCV-13, 13-valent pneumococcal conjugate vaccine; PHiD-CV, 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine.
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http://www.biomedcentral.com/1471-2458/13/1025and its lower price per dose in the PAHO Revolving Fund.
Overall, PCV-13 is dominated by PHiD-CV because
PHiD-CV generates 50 more QALYs gained at a reduced
cost of US$ 3.4 million (discounted data), but it is more
cost effective than PCV-7. Similar to the scenario without
quality of life, PHiD-CV is predicted to be cost saving
compared to PCV7 (generates 769 additional QALYs at a
reduced cost of US$ 2.1 million). The PSA shows that
PCV-13 is dominated by PHiD-CV in 84% of the simula-
tions, and PHiD-CV presents a better economic profile in
the other 16% of the simulations.
It is important to evaluate our results after considering
several assumptions with the input data used in this model.
The most important assumption is the paucity of efficacy
data for the new vaccines. This limitation was minimized
by using estimates of vaccine efficacy based on serotype-
specific efficacies for ID demonstrated for the pneumococ-
cal serotypes included in PCV-7 [24] and the pneumococcalserotype prevalence in ID described by the SIREVA surveil-
lance network for Peru [21,22]. A recent study [52] on the
efficacy of PHiD-CV against ID confirms our efficacy
assumptions. For pneumonia, various clinical trials of
different PCVs and a Cochrane review [25-31,33-35] do
not show a relationship between pneumococcal type cover-
age and efficacy against pneumonia outcomes. Therefore,
we used the same efficacy estimates against pneumonia for
all three vaccines using data from a recently completed
clinical trial of PHiD-CV (performed entirely in Latin
American countries) to determine its efficacy against
pneumonia [33-35]. Another limitation of this analysis
is the quality of the epidemiological data available for
Peru, which may impact on the accuracy of the assess-
ment of the cost-effectiveness of these vaccines. We
based our disease burden estimations on mortality data
and other statistics reported for Peru, but also on expert
opinion consultations when information was missing.
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ously published [14], but we recognize this limitation
and the uncertainty around these input. Published esti-
mates of pneumococcal disease burden generated for the
Latina region by two international organizations - the
Sabin Vaccine Institute/Pan American Health Organization
[2] and the WHO [1] - were significantly different. This is
probably as a result of different literature review processes
or modeling strategies, but it shows the difficulties of
this task and should not be ignored when these results
are analyzed. Although great efforts were taken to assess
the completeness and coverage of the reporting systems
evaluated and used in the present study, this is an im-
portant limitation to consider when analyzing this cost
effectiveness study.
We can compare our results with other cost-effectiveness
studies comparing PCVs, particularly in Latin American
countries [53-55]. Muciño-Ortega et al. [53] presented
an analysis of PCVs for Mexico and showed PCV-13 to
be dominant over PHiD-CV and PCV-7. They showed,
surprisingly, that PCV-13 (with three additional pneumo-
coccal types) is expected to prevent three times as many
deaths as PHiD-CV. This study used ecological studies
to estimate vaccine efficacy against pneumonia, ignoring
many clinical trials of PCVs against this specific out-
come. In addition, they adjusted vaccine efficacy against
pneumonia with the estimated serotype coverage for each
vaccine. Finally, they did not consider the vaccine efficacy
of PHiD-CV against AOM-related outcomes generated by
Prymula et al. [13]; instead, they calculated an adjusted
vaccine efficacy against AOM based on selected immuno-
genicity data comparing PHiD-CV and PCV-7. It is diffi-
cult to analyze their overall results when they prioritized
the use of ecological or immunogenicity studies over
clinical trials for the estimation of vaccine efficacy.
Urueña et al. [54] described that either PHiD-CV or
PCV-13 would be cost effective for Argentina, with ICERs
of US$ 8,973/DALY and US$ 10,948/DALY, respectively.
Their analysis shows better incremental cost differences
for PHiD-CV (at price parity per dose) and better incre-
mental health gains for PCV-13. Although they mentioned
that serotype coverage adjustments were not assumed for
vaccine efficacy against consolidated pneumonia (same
assumption that we used; equal vaccine efficacy), the
most significant difference in health gains between the
vaccines was the differential vaccine effects observed
against pneumonia. If vaccine effects on consolidated
pneumonia were adjusted in line with their methods
and our assumptions, both studies would be very much
aligned in their conclusions. Lastly, Castañeda-Orjuela et al.
[55] have described that PHiD-CV and PCV-13 would be
cost-effective interventions in Colombia, with ICERs of
US$ 1,837/LY and US$ 2,742/LY, respectively. This ana-
lysis also shows better incremental health gains forPCV-13, but no evaluation of quality of life was included
in the base-case or any other scenario analyzed. In
addition, this study also reports better incremental cost
differences for PHiD-CV (compared to PCV-13), based
on its better profile against AOM, although prices per
dose were not totally comparable. They used US$ 14.85
for PHiD-CV (price for the PAHO 2011 RF) and US$ 16.34
for PCV-13. Although the price for PCV-13 was provided
by the Ministry of Health this was the vaccine price for
the PAHO 2012 RF, and was not available in 2011 for
any public source. In conclusion, the latest two studies
are in agreement with our conclusion for vaccine com-
parison, in the scenario without considering quality of
life. The additional health benefits provided by PCV-13
over PHiD-CV require significant investment and the
ICER is over the 1 GDP per capita threshold defined for
developing countries [48,49]. Overall, the results pre-
sented in these Latin American studies [54,55] are well
aligned with each other, and if inconsistencies were re-
moved (differential vaccine effects on pneumonia for the
Argentine study [54]) or more complete scenarios were
evaluated (quality of life included in the Colombian study
[55]), the conclusions of these two studies would be even
closer to ours, highlighting the robustness of our study.
Our results could change slightly if vaccine prices at
the PAHO RF were different. We analyzed the scenario
with equal vaccine prices and showed that part of the
cost benefits identified for PHiD-CV is reduced. Never-
theless, PHiD-CV will still generate additional QALYs
gained at a reduced cost (compared to PCV-13) in this
modified scenario for vaccine costs. Both PCV-13 and
PHiD-CV have participated in the PAHO RF fund since
2012 and PHiD-CV consistently presented reduced cost
per dose compared to PCV-13.
Although this is purely a modeling exercise, with all its
caveats, the information presented is a critical tool for
decision makers because it is the only way to merge dif-
ferent evidences in order to generate one analysis for
decision-making purposes. Dissemination of this infor-
mation will contribute to evidence-based decision-making
about the introduction of new vaccines in Latin American
countries.
Conclusions
The results of this modeling study predict that PCVs are
likely to be a cost-effective strategy to help relieve the
epidemiological and economic burden associated with
pediatric pneumococcal and NTHi diseases for Peru.
PHiD-CV is likely to be a dominant (better health gains
at a reduced net cost) intervention compared to PCV-13
or PCV-7. The most significant drivers for these results
are the better health and economic profile of PHiD-CV
against AOM and its reduced cost per dose available
through the PAHO Revolving Fund in the LAC region.
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